Figure 2.

Cell growth inhibitory activities of 6 PA-derived compounds against human cancer cells in vitro. (A) Cell growth inhibition of HepG2 liver cancer, HCT116 and HT29 colon cancer, and A549 lung cancer cells treated with 50 µg/ml PA compounds YS206, YS207, YS208, YS306, YS307 and YS308. (B-D) Various concentrations (1–50 µg/ml) of YS206, YS306 and the anticancer drug paclitaxel were used to treat HepG2, HCT116 and HT29 cells and growth inhibition was examined. PA, phenanthroindolizidine alkaloid.